Table 3. Differences in biochemical responses to placebo vs. slow sodium by sex.
| Variable | Males (n=24) | Females (n=24) | ||||
|---|---|---|---|---|---|---|
|
|
||||||
| Placebo | Slow sodium | P-value | Placebo | Slow sodium | P-value | |
| Serum measurements | ||||||
| Na+, mmol/l | 140±0.4 | 141±0.3 | 0.001 | 139±0.3 | 140±0.4 | < 0.001 |
| Cl-, mmol/l | 103±0.4 | 106±0.5 | < 0.001 | 103±0.4 | 105±0.6 | < 0.001 |
| K+, mmol/l | 4.4±0.06 | 4.4±0.07 | 0.97 | 4.3±0.07 | 4.3±0.09 | 0.69 |
| eGFR, ml/min/1.72m2 | 114.7 (103.9 – 127.5) | 117.1(107.3 – 136.7) | 0.24 | 99.2 (84.1 – 119.2) | 105.9 (94.2-127.8) | < 0.001 |
| Plasma measurements | ||||||
| Renin, mU/l | 24(15–30) | 11(4–13) | < 0.001 | 17 (9 – 21) | 3 (2 – 7) | < 0.001 |
| Aldosterone, pmol/l | 221(143–318) | 80(69–111) | < 0.001 | 240 (137 – 435) | 69 (69 – 75) | < 0.001 |
| VEGF-C, pg/ml | 540 (352 – 881) | 625 (460 – 1066) | 0.20 | 830 (467 – 1404) | 755 (412 – 1130) | 0.39 |
| SFLT-4, pg/ml | 8.9±1.1 | 9.1±1.0 | 0.79 | 10.3±1.0 | 10.6±0.9 | 0.57 |
| Urinary measurements | ||||||
| Volume, ml/24hr | 1540±174 | 1678±203 | 0.25 | 1935±166 | 2299±186 | 0.004 |
| Na+, mmol/24hr | 86.3±10.3 | 221.9±16.5 | < 0.001 | 60.0±6.8 | 227.1±19.9 | < 0.001 |
| Cl-, mmol/24hr | 103.7±11.6 | 228.1±14.4 | < 0.001 | 83.8±8.2 | 241.3±21.5 | < 0.001 |
| K+, mmol/24hr | 63.3(51.2 – 93.5) | 55.1(39.9 – 73.8) | 0.15 | 56.9(40.5 – 76.7) | 58.7(41.6 – 77.9) | 0.49 |
| Creatinine clearance, ml/min | 111.1±9.1 | 125.3±9.6 | 0.14 | 108.1±8.0 | 122.4±7.6 | 0.06 |
| Fractional ExcretionNa, % | 0.44±0.06 | 0.93±0.08 | < 0.001 | 0.28±0.03 | 0.94±0.09 | < 0.001 |
Normally distributed data presented as mean±SEM. Non-normally distributed data are presented as median and IQR